This is a preview of subscription content, log in via an institution to check access.
Notes
Comparative Effectiveness Public Advisory Council
References
Institute for Clinical and Economic Review. Institute for Clinical and Economic Review's Updated Assessment of New Targeted Therapies for Plaque Psoriasis Notes Minor Distinctions in Effectiveness, While Recent Price Hikes Have Made Entire Drug Class Less Cost-Effective. Internet Document : 12 Jun 2018. Available from: URL: https://icer-review.org/announcements/psoriasis-update/.
Institute for Clinical and Economic Review. Institute for Clinical and Economic Review Report Questions the Adequacy of Evidence on Overall Health Benefit of Elagolix Given Limitations of Information on Safety and Limited Evidence Comparing to Other Treatment Options. Internet Document : 15 Jun 2018. Available from: URL: https://icer-review.org/announcements/endo-evidence-report/.
Institute for Clinical and Economic Review to Assess Canakinumab for Atherosclerosis. Internet Document : 18 Jun 2018. Available from: URL: https://icer-review.org/announcements/atherosclerosis-topic/.
Rights and permissions
About this article
Cite this article
ICER reports on psoriasis drugs, elagolix, canakinumab. PharmacoEcon Outcomes News 806, 1 (2018). https://doi.org/10.1007/s40274-018-5044-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5044-6